INTRODUCTION
Inhaled histamine is as useful as methacholine for measuring airway responsiveness in asthmatics. However, such side effects as throat irritation, flushing, and headache are more frequent with histamine than with methacholine, and are doserelated (1) . It is possible that the inhaled histamine produces severe adverse effects in asthmatics with increased end organ responsiveness to histamine.
The pathogenesis of urticaria and angioedema can involve the release of a diverse array of potential vasoactive mediators that arise from the activation of cells or enzymatic pathways, and histamine appears to be the major culprit (2) . It has been reported that skin responses to histamine are enhanced in patients with chronic idiopathic urticaria (3). Therefore, inhaled histamine is likely to develop some adverse effects easily in patients with chronic idiopathic urticaria and/or angioedema. To our knowledge, the patient described herein is the first case of severe oropharyngeal angioedema developed during histamine inhalation challenge in an asthmatic patient with chronic idiopathic angioedema.
CASE REPORT
A 56-yr-old woman visited our clinic for evaluation of chronic cough and breathlessness. She had experienced mild angioedema episodes involving face and/or extremities without a family history. The episodes had no clear-cut association with any food, drugs or physical factors. Nephelometric assays (Behring, U.S.A.) showed normal C3 (135.4 mg/dL) and C4 (23.3 mg/dL) levels. Radial immunodiffusion assay (Binding Site, U.K.) showed that C1 esterase inhibitor was 37 mg/dL (normal range, 15-35 mg/dL). These findings could exclude the diagnosis of hereditary angioedema. On visit, she had no angioedema. Spirometry showed 1,980 mL (85% of predicted value) of forced expiratory volume in one second (FEV1) and 2,550 mL (89%) of forced vital capacity. Skin prick tests with routine inhalants showed positive responses to Dermatophagoides pteronyssinus and D. farinae.
Regarding the diagnosis of asthma, methacholine challenge test was performed according to the standardized tidal breathing method (4) . The concentration of methacholine that produced 20% fall in FEV1 from baseline (PC20) was over 25 mg/mL. Five days later, histamine inhalation challenge test was performed (4), inhaling doubling concentrations of histamine acid phosphate (Sigma Chemical Co., U.S.A.) from 0.03 to 16 mg/mL. FEV1 fell by 37% from baseline at 3 min after inhalation of 8 mg/mL, resulting in histamine-PC20 of 4.59 mg/mL. Immediately thereafter, severe angioedema on face, lips, and oropharyngeal area, foreign body sensation at throat, and hoarseness occurred (Fig. 1) . The angioedema was
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To assess end organ responsiveness to histamine, skin prick tests with doubling concentrations of histamine from 0.03 to 16 mg/mL were performed in duplicate on the forearm of the patient and six age-and sex-matched controls with atopic asthma. All subjects submitted a written consent to participate in the study. Fifteen minutes after the histamine prick test, the wheals corresponding to each of histamine concentrations were drawn directly on the arm. Tape was applied, removed, and glued onto a transparency, permitting an exact tracing of each area. All areas were calculated after scanning and integration using the computer program Adobe Photoshop and were analyzed using the public domain National Institutes of Health (NIH) Image program (developed at the US NIH and available on the Internet at http://rsb.info.nih. gov/nih.gov/nih-image/). The cut-off value of the skin response was determined from mean plus 2-fold standard deviation of wheal area from the controls. (Fig. 2) . Also, regression analysis showed that the intercept (25.9 mm 2 ) and slope (23.0) were greater than the cut-off values (20.6 mm 2 for intercept and 21.6 for slope) determined from six controls.
DISCUSSION
In the present case, the fact that oropharyngeal angioedema was induced by histamine, but not by methacholine, suggests that inhaled histamine is the culprit for the reaction. A vasodilation response of histamine is mediated through both H1 and H2 receptor subtypes, and this response is mediated in part by endothelium-derived relaxing factor (5). Although side effects to inhaled histamine are dose-related (1), the histamine concentration (8 mg/mL) producing the oropharyngeal angioedema in our patient was not very high. This may suggest that the increased end organ responsiveness to histamine enhances the effects of histamine at its receptors. Krause and Shuster (3) reported that the wheal and flare response to histamine was enhanced in patients with chronic idiopathic urticaria as compared with normal subjects. Similarly, our case of atopic asthma and chronic idiopathic urticaria showed a greater skin response to histamine compared with age-and sex-matched atopic asthmatics, indicating the enhanced end organ responsiveness to histamine, which may contribute to the occurrence of the oropharyngeal angioedema by inhaled histamine.
In addition, Kanny et al. (6) showed that abnormal passage of histamine across the intestinal barrier could result either from intestinal hyperpermeability and/or a deficit in the enzymatic catabolism of histamine in chronic idiopathic urticaria, postulating a deficit in diamine oxidase in the enterocytes. The increased absorption of inhaled histamine across the oropharyngeal mucosa may in part play a role in the development of the angioedema in the present case.
Although airway responsiveness to histamine correlated closely with responsiveness to methacholine (1), our case showed different airway responses to both stimuli. Spector and Farr (7) reported that atopic asthmatics were more reactive to histamine than to methacholine. However, further investigations are needed to verify this.
Taken together, in case the histamine bronchial provocation test is performed in asthmatics with a history of chronic idiopathic urticaria and/or angioedema, a possibility of severe oropharyngeal angioedema by inhaled histamine should be considered.
